New antibiotics targeting drug-resistant Gram-negative bacterial infections
Novel Biamyxins targeting multidrug resistant Gram-negative bacterial infections
This study is working on a new type of antibiotic called biamyxins to help fight tough infections caused by bacteria that don't respond to regular treatments, especially for patients dealing with serious healthcare-related infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10859228 on NIH RePORTER |
What this research studies
This research focuses on developing a new class of antibiotics called biamyxins, which are designed to combat multidrug-resistant Gram-negative bacteria that cause serious healthcare-associated infections. The approach involves creating semisynthetic peptides that bind to the outer membrane of these bacteria, enhancing their effectiveness against strains that are resistant to current treatments. By targeting specific pathogens like Acinetobacter baumannii, this research aims to provide a broader spectrum of antimicrobial activity. Patients with infections caused by these resistant bacteria may benefit from the novel treatments being developed.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with infections caused by multidrug-resistant Gram-negative bacteria, particularly those who have not responded to existing antibiotics.
Not a fit: Patients with infections caused by non-Gram-negative bacteria or those who are not infected may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective new treatments for patients suffering from difficult-to-treat bacterial infections.
How similar studies have performed: Other research has shown promise in developing new antibiotics for resistant bacteria, indicating that this approach could be a viable solution.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Zhao, Yanan — State University of New York at Buffalo
- Study coordinator: Zhao, Yanan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.